

NC-MEDI-CAPS LIMITED

Regd. Office and works:

Mhow - Neemuch Road, Sector 1, CIN: L70100MP1983PLC002231
Pithampur - 454775, Dist. Dhar
Madhya Pradesh, India

Ph:- 07292-256205

Fax:- 0731-4041435

E mail:- investors@medicaps.com

Website:- www.medicaps.com

MCL/SE/2022-2023

Date: 04th August, 2022

Online filing at: www.listing.bseindia.com

To,
The General Manager
DCS-CRD
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street Fort, Mumbai – 400001 (M.H.)

Subject: Submission of the Standalone and Consolidated Unaudited Financial Results for the Quarter ended on 30th June, 2022 as per Regulation 33(3) of SEBI (LODR) Regulations, 2015.

Ref: MEDI-CAPS LIMITED (BSE Scrip Code: 523144, ISIN: INE442D01010)

Dear Sir/Madam,

This is in Continuation of our letter no. MCL/BM/SE/2022-2023 dated 26th July, 2022 regarding intimation of Board of Directors meeting for Consideration and approval of Standalone as well as Consolidated Un-Audited Financial Results for the Quarter ended on 30th June, 2022.

We are pleased to inform that, In compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Audit Committee and Board of Directors at their respective meetings held on 04th August, 2022 has considered and approved the following businesses:-

- (a) Unaudited Standalone and Consolidated Financial Results for the quarter ended on 30th June, 2022; and
- (b) Limited Review Report by the Statutory Auditors of the Company for the Unaudited Standalone and Consolidated quarter ended on 30th June, 2022.

We are also in process of filing the aforesaid Unaudited financial results in the XBRL format within the stipulated time.

The aforesaid results shall also be uploaded on the Company's website www.medicaps.com and on the website of the Stock Exchange i.e., at www.bseindia.com. Further, the extract of aforesaid results shall also be published in Hindi (vernacular) and widely circulated English Newspaper.

*Corporate Office: 201, Pushpratna Paradise 9/5 New Palasiya,
Opposite UCO Bank Indore (M.P.) 452001
Contact No: 0731-4028148*

NCP MEDI-CAPS LIMITED

Regd. Office and works:

Mhow - Neemuch Road, Sector 1, CIN: L70100MP1983PLC002231

Pithampur - 454775, Dist. Dhar

Madhya Pradesh, India

Ph:- 07292-256205

Fax:- 0731-4041435


E mail:- investors@medicaps.com

Website:- www.medicaps.com


You are requested to please take on record the aforesaid Unaudited Financial Results along with Limited review Report for your records and reference.

Thanking You,

FOR, MEDI-CAPS LIMITED



ALOK K. GARG
MANAGING DIRECTOR
DIN: 00274321



Encl.: Unaudited Standalone and Consolidated Financial Results along with limited review report for the quarter ended 30th June, 2022.

*Corporate Office: 201, Pushpratna Paradise 9/5 New Palasiya,
Opposite UCO Bank Indore (M.P.) 452001
Contact No: 0731-4028148*

RAWKA & ASSOCIATES

CHARTERED ACCOUNTANTS

412, Arcade Silver 56, 1, New Palasia, Indore - 1

☎ Off. : 2541132, Mobile : 9039080380

E-mail : rawkaassociates@gmail.com, cprawka@gmail.com

Limited Review Report on Unaudited Standalone Financial Results for the quarter ended 30th June, 2022 of Medi-Caps Limited ('the Company') pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,
The Board of Directors of
Medi-Caps Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of MEDI-CAPS LIMITED ("the Company") for the quarter ended June 30th, 2022 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'), including relevant circulars issued by the SEBI from time to time. The Statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors. Our responsibility is to issue a report on the Statement based on our review of the Statement, which has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), specified under Section 133 of the Companies Act, 2013 read with relevant rules issued there under, and other accounting principles generally accepted in India and in Compliance with Regulation 33 of the Listing Regulations.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian accounting standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognised accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Indore

Date: 04/08/2022

UDIN: 22429040AOFPWY6145

For: Rawka & Associates

(Chartered Accountants)

FRN 021606C



Venus Rawka
Venus Rawka
(Partner)

M. No. 429040


Limited Review Report On Unaudited Consolidated Quarterly Financial Results of Medi-Caps Limited (the Parent Company) for the quarter ended 30th June, 2022 Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors of
Medi-Caps Limited

1. We have reviewed the accompanying Statement of the Consolidated Unaudited Financial Results ("the Statement") of Medi-Caps Limited ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group"), and its share of the net profit after tax and total comprehensive profit for the quarter ended June 30, 2022, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"), including relevant circular issued by the SEBI time to time.

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of its wholly owned subsidiary Medgel Private Limited.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of its subsidiary, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. Our conclusion is not modified in respect of this matter.

7. The consolidated unaudited financial results includes the interim financial statements / financial information/ financial results of Medgel Private Limited (wholly owned subsidiary) which also have been reviewed by us and certified by the management, whose interim consolidated financial statements/ financial information/ financial results reflect total revenue of Rs 1217.25 Lakhs, total net profit after tax of Rs. 74.85 Lakhs and total comprehensive income of Rs. 52.03 Lakhs for the quarter ended June 30, 2022, as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial statements/ financial information/ financial results are not material to the group.

Our Conclusion on the statement is not modified in respect of above matter.

Place: Indore

Date: 04/08/2022

UDIN: 22429040AOFPAT6958

For: Rawka & Associates

(Chartered Accountants)

FRN: 021606C



A handwritten signature in black ink, appearing to be "Venus Rawka".

Venus Rawka
(Partner)

M.No. 429040


XV	Profit/(loss) for the period (X+XIII)	(15.99)	16.90	(5.49)	(3.80)	58.87	149.59	334.82	1008.04
XVI	Other comprehensive income								
	(a) (i) items that will not be reclassified to statement of profit & loss	-24.48	6.44	26.09	35.69	-47.30	24.11	65.33	146.32
	(ii) Income tax on items that will not be reclassified to statement of P& L	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	(b) (i) items that will be reclassified to statement of profit & loss	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax on items that will be reclassified to statement of P& L	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Other comprehensive income :	-24.48	6.44	26.09	35.69	-47.30	24.11	65.33	146.32
XVII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	-40.47	23.34	20.60	31.89	11.57	173.70	400.15	1154.36
XVIII	Profit or Loss Attributable to								
	Profit or Loss Attributable to owners of Parents	0.00	0.00	0.00	0.00	58.87	149.59	334.82	1008.04
	Profit or Loss Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
XIX	Total Comprehensive Income for the period Attributable to								
	Total Comprehensive Income for the period Attributable to owners of Parents	0.00	0.00	0.00	0.00	11.57	173.70	400.15	1154.36
	Total Comprehensive Income for the period Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
XX	Paid-up equity share capital of the company (Face value Rs.10/- Per Share)	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00
XXI	Reserves excluding revaluation reserves	0.00	0.00	0.00	4881.80	0.00	0.00	0.00	10378.60
XXII	Earnings per equity share (for continuing operation)								
	a) Basic (Rs.)	-0.09	0.10	(0.10)	(0.06)	0.51	1.17	2.63	8.05
	b) Diluted (Rs.)	-0.09	0.10	(0.10)	(0.06)	0.51	1.17	2.63	8.05
	Earnings per equity share (for discontinued operation)								
	a) Basic (Rs.)	-0.03	0.03	0.05	0.03	(0.03)	0.03	0.05	0.03
	b) Diluted (Rs.)	-0.03	0.03	0.05	0.03	-0.03	0.03	0.05	0.03
	Earnings per equity share (for discontinued and continuing operation)								
	a) Basic (Rs.)	-0.12	0.13	(0.05)	(0.03)	0.48	1.20	2.68	8.08
	b) Diluted (Rs.)	-0.12	0.13	(0.05)	(0.03)	0.48	1.20	2.68	8.08

DATE : 04.08.2022

PLACE : INDORE

For MEDI-CAPS LIMITED

ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321



MEDI-CAPS LIMITED

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1, PITHAMPUR-454775, DISTT. DHAR (M.P.), Tel: 07292-256205, Fax: 0731-4041435

Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231

Consolidated Segmentwise Revenue, Results and Capital Employed for Quarter ended 30th June, 2022



(Amount in Lakhs)

S.No.	Segment Revenue	Quarter Ended			Year Ended
		June 30,	March 31,	June 30,	March 31,
		2022	2022	2021	2022
		unaudited	Audited	unaudited	Audited
1	Segment Revenue				
	Pharma Division	1,266.16	1,885.64	1,733.13	7,117.80
	Real Estate Division	2.62	14.31	1.27	60.74
	Other	0.00	0.00	0.00	0.00
	Net Sales/Income From Operations	1,268.78	1,899.95	1,734.40	7,178.53
2	Segment Results (Profit) (+)/ Loss (-) before tax and Interest				
	Pharma Division	74.97	132.69	340.31	1,011.87
	Real Estate Division	(11.68)	14.20	(12.32)	(6.08)
	Other	0.00	0.00	0.00	0.00
	Total	63.30	146.89	327.99	1,005.79
	Interest Income	0.00	0.00	0.00	0.00
	Interest Expenses	0.12	0.00	0.00	0.02
	Other Unallocable Expenditure net off	0.00	0.00	0.00	0.00
	Unallocable Income	0.00	0.00	0.00	0.00
	Profit Before Tax	63.18	146.89	327.99	1,005.77
	Current Tax	0.00	0.00	0.00	0.00
	Deferred Tax	0.00	1.44	0.00	1.44
	Profit After Tax	63.18	145.45	327.99	1,004.32

3	Capital Employed				
	Segment Assets (A)				
	Pharma Division	12,434.16	12,861.34	11,695.98	12,861.34
	Real Estate Division	171.40	173.71	100.00	173.71
	Other	0.00	0.00	0.00	0.00
	Total (A)	12,605.56	13,035.05	11,795.98	13,035.05
	Segment Liabilities (B)				
	Pharma Division	968.40	1,409.45	824.60	1,409.45
	Real Estate Division	0.00	0.00	100.00	0.00
	Other	0.00	0.00	0.00	0.00
	Total (B)	968.40	1,409.45	924.60	1,409.45
4	Total Capital Employed (Segment Assets- Segment Liabilities)				
	Pharma Division	11,465.76	11,451.88	10,871.38	11,451.88
	Real Estate Division	171.40	173.71	0.00	173.71
	Other	0.00	0.00	0.00	0.00
	Total Capital Employed (Segment Assets- Segment Liabilities)	11,637.16	11,625.59	10,871.38	11,625.59

DATE : 04/08/2022
PLACE: INDORE

For MEDI-CAPS LIMITED

ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

NOTES:

1. The above unaudited financial results for the Quarter ended June 30, 2022 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on August 4, 2022. The above results have been reviewed by statutory Auditors of the Company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, who have expressed an unmodified opinion.
2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
3. The above consolidated financial results includes the result of Wholly Owned Subsidiary Company i.e. Medgel Private Limited.
4. The Company has two reportable segments for the Consolidated Financial Statements which consists Pharma division and Real Estate division in accordance with Ind AS-108 Operating Segment and same is enclosed with this financial result.
5. The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary.
6. The aforesaid Un-audited financial Results will be uploaded on the Company's website www.medicaps.com and will also be available on the websites of the Stock exchange i.e. www.bseindia.com for the benefit of shareholders and investors.
7. The discontinuation of manufacturing activities is consistent with the Company's long-term strategy to focus its activities in the areas of Real Estate Business and to divest unrelated activities. Accordingly, Loss for the quarter ended June 30, 2022 is from discontinuing operation.
8. M/s Tirupati Reality & Developers, The developer had received the approval of RERA ("Real Estate Regulatory Authority") for the project 'Medicaps Business Park' dated 17th March, 2022 and the Bookings have been started by Tirupati Reality & Developers.
9. Description of Income & Expenditure of Discontinue operations


(Amount in Lakhs)

	Particulars	3 Month Ended	3 Months Ended
		30.06.2022	31.03.2022
I	Income from operations	0.00	0.00
II	Other Income	0.00	11.94
III	Total income (I+II)	0.00	11.94
IV	Expenses		

	a) Changes in Inventories of finished goods, & work in progress	0.00	4.94
	b) Employee benefits expense	0.00	0.00
	c) Finance Cost	0.00	0.00
	d) Depreciation expense	2.24	0.44
	e) Other expenses	2.07	2.42
	Total Expenses (IV)	4.31	7.80
V	Net Profit/Loss From Discontinue Operation	-4.31	4.14

DATE : 04.08.2022
PLACE: INDORE

For, MEDI-CAPS LIMITED



ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

